---
schema_version: "secwatch.filing_event.v1"
accession: "0001070081-25-000011"
form_type: "8-K"
ticker: "PTCT"
cik: "0001070081"
company_name: "PTC THERAPEUTICS, INC."
filed_at: "2025-02-27T23:59:59+00:00"
generated_at: "2026-05-26T00:58:28.770635+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# PTC Therapeutics reports FY2024 revenue $807M above guidance; cash >$2B after Novartis deal

## Summary
- FY2024 total revenue $806.8M, exceeding guidance; net loss $363.3M vs $626.6M prior year.
- Cash and marketable securities $1.14B at Dec 31, 2024; >$2B after Jan 2025 Novartis PTC518 deal.
- Four NDAs accepted by FDA in 2024; sepiapterin PDUFA July 29, 2025, vatiquinone priority review Aug 19, 2025.
- FY2025 revenue guidance $600-800M; GAAP R&D+SG&A $805-835M; cash supports commercial and R&D plans.
- DMD franchise revenue $144M in Q4; Translarna $93.7M, Emflaza $50.5M; Evrysdi royalties $203.9M in FY2024.

## SEC filing metadata
- accession: 0001070081-25-000011
- form_type: 8-K
- ticker: PTCT
- cik: 0001070081
- company_name: PTC THERAPEUTICS, INC.
- filed_at: 2025-02-27T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1070081/000107008125000011/0001070081-25-000011-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1070081/000107008125000011/tmb-20250227x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001070081-25-000011
- JSON: https://secwatch.observer/filing/0001070081-25-000011.json
- Plain text: https://secwatch.observer/filing/0001070081-25-000011.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.